Oramed Pharmaceuticals Newsroom

H.C. Wainwright Maintains Oramed Pharmaceuticals(ORMP.US) With Hold Rating

Moomoo NewsSep 9, 2024 06:33 ET

Oramed Pharmaceuticals Analyst Ratings

BenzingaSep 9, 2024 06:12 ET

Oramed Pharmaceuticals Analyst Ratings

BenzingaMay 20, 2024 07:22 ET

Canaccord Genuity Adjusts Price Target on Oramed Pharmaceuticals to $2 From $3, Maintains Hold Rating

MT NewswiresMay 17, 2023 10:24 ET

Canaccord Genuity Maintains Hold on Oramed Pharmaceuticals, Lowers Price Target to $2

BenzingaMay 17, 2023 10:08 ET

Oramed Pharmaceuticals Analyst Ratings

Benzinga Analyst RatingsJan 17, 2023 06:13 ET

Cantor Fitzgerald Downgrades Oramed Pharmaceuticals to Neutral From Overweight, Adjusts Price Target to $5 From $20

MT NewswiresJan 12, 2023 09:21 ET

Oramed Pharmaceuticals Analyst Ratings

Benzinga Analyst RatingsJan 12, 2023 06:53 ET

H.C. Wainwright Sticks to Its Buy Rating for Oramed Pharmaceuticals (ORMP)

TipRanksJan 3, 2023 06:20 ET

Analysts Offer Insights on Healthcare Companies: Precision BioSciences (DTIL) and Oramed Pharmaceuticals (ORMP)

TipRanksAug 15, 2022 07:00 ET

Analysts Offer Insights on Healthcare Companies: Kazia Therapeutics (KZIA), EyePoint Pharmaceuticals (EYPT) and Oramed Pharmaceuticals (ORMP)

TipRanksAug 2, 2022 06:20 ET

Analysts Offer Insights on Healthcare Companies: MacroGenics (MGNX), KalVista Pharmaceuticals (KALV) and Oramed Pharmaceuticals (ORMP)

TipRanksJul 11, 2022 06:22 ET